Please wait
0001601830424B5EX-FILING FEESClass A Common Stock, par value $0.00001 per shareRecursion Pharmaceuticals, IncS-3 0001601830 2025-02-27 2025-02-27 0001601830 1 2025-02-27 2025-02-27 0001601830 1 2025-02-27 2025-02-27 0001601830 2 2025-02-27 2025-02-27 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107
Filed Pursuant to Rule 424(b)(5)
Registration
No. 333-284878
Calculation of Filing Fee Tables
424(b)(5)
(Form Type)
Recursion Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Table 1 – Newly Registered Securities and Carry Forward Securities
 
                         
     Security
Type		  
Security
Class
Title
   Fee
Calculation
Rule		  
Amount
registered
   Proposed
maximum
offering
price per
Unit		  
Maximum
aggregate
offering
price
  
Fee
Rate
  
Amount of
registration
fee
   Carry
Forward
From
Type		   Carry
Forward
File
Number		   Carry
Forward
Initial
Effective
Date		   Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
                         
Fees to be
Paid
   Equity  
Class A
Common Stock, par value $0.00001 per share		   457(o) and 457(r)
(1)
   $500,000,000   —   $500,000,000   0.00015310   $76,550.00   —   —   —   —
 
Carry Forward Securities
                         
Carry
Forward
Securities
   —   —   —   —   —   —   —   —   —   —   —   —
                   
    Total Offering Amounts   —   $500,000,000   —   $76,550.00   —   —   —   —
                   
    Total Fees Previously Paid   —   —   —   —   —   —   —   —
                   
    Total Fee Offsets   —   —   —   $10,438.53
(2)
   —   —   —   —
                   
    Net Fee Due   —   —   —   $66,111.47   —   —   —   —
Table 2 – Fee Offset Claims and Sources
 
                       
    
Registrant
or Filer
Name
  
Form
or
Filing
Type
  
File
Number
  
Initial
Filing
Date
  
Filing
Date
  
Fee
Offset
Claimed
   Security
Type
Associated
with Fee
Offset
Claimed		  
Security
Title
Associated
with Fee
Offset
Claimed
   Unsold
Securities
Associated
with Fee
Offset
Claimed		  
Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset Claimed
  
Fee
Paid
with
Fee
Offset
Source
 
Rule 457(p)
                       
Fee Offset
Claims
  
Recursion Pharmaceuticals, Inc.
  
S-3
  
333-264845
   May 10, 2022   —   $10,438.53
(2)
   Equity   Class A Common Stock, par value $0.00001 per share   —   $94,723,515.62   —
                       
Fee Offset
Sources
   Recursion Pharmaceuticals, Inc.  
424B5
  
333-264845
   —   August 8, 2023   —   —   —   —   —   $33,060.00
 
(1)
In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the “Securities Act”), the registrant initially deferred payment of all of the registration fees for the Registration Statement on Form
S-3ASR
(File
No. 333-284878),
filed on February 12, 2025 (the “Registration Statement”). This “Calculation of Filing Fee Table” shall be deemed to update the “Calculation of Registration Fee” table in the Registration Statement. The prospectus to which this Exhibit is attached is a final prospectus supplement for the related offering.
 
(2)
The registrant previously registered shares of Class A Common Stock having an aggregate offering price of up to $300,000,000, offered by means of a 424(b)(5) prospectus supplement, dated August 8, 2023 (the “Prior Prospectus Supplement”), pursuant to a Registration Statement on Form
S-3ASR
(File
No. 333-264845),
filed with the Securities and Exchange Commission on May 10, 2022 (the “Prior Registration Statement”). In connection with the filing of the Prior Prospectus Supplement, the registrant made a contemporaneous fee payment in the amount of $33,060.00. As of the date of filing of this prospectus supplement, shares of Class A Common Stock having an aggregate offering price of up to $94,723,515.62 remain unsold under the Prior Prospectus Supplement (the “Unsold Shares”). Pursuant to Rule 457(p), $10,438.53 in filing fees previously paid and associated with the Unsold Shares (calculated at the fee rate in effect on the filing date of the Prior Prospectus Supplement) is being applied to partially offset the filing fee payable in connection with this filing and the offering pursuant to the Prior Prospectus Supplement has been terminated.
 
-2-